CanDo

A CANcer Development mOnitor

Coordinatore	UNIVERSITAT DE VALENCIA    more  Organization address address: AVENIDA BLASCO IBANEZ 13 city: VALENCIA contact info Titolo: Mrs. Nome: Angeles Cognome: Sanchis Email: send email Telefono: +34 96 3983621 Fax: +34 96 3937729
Nazionalità Coordinatore	Spain [ES]
Totale costo	5˙299˙286 €
EC contributo	4˙000˙000 €
Programma	FP7-ICT Specific Programme "Cooperation": Information and communication technologies
Code Call	FP7-ICT-2013-10
Funding Scheme	CP
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-01-01   -   2017-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAT DE VALENCIA  Organization address address: AVENIDA BLASCO IBANEZ 13 city: VALENCIA contact info Titolo: Mrs. Nome: Angeles Cognome: Sanchis Email: send email Telefono: +34 96 3983621 Fax: +34 96 3937729	ES (VALENCIA)	coordinator	0.00
2	Bayer Pharma AG  Organization address address: Muellerstrasse 178 city: Berlin contact info Titolo: Dr. Nome: Thomas Cognome: Krahn Email: send email Telefono: +49 202364125	DE (Berlin)	participant	0.00
3	GILUPI GMBH  Organization address address: AM MUEHLENBERG 11 city: POSTDAM contact info Titolo: Dr. Nome: Klaus Cognome: Luecke Email: send email Telefono: 4933160000000 Fax: +49 33158184780	DE (POSTDAM)	participant	0.00
4	IKERLAN SCL  Organization address address: Paseo J.M. Arizmendiarrieta 2 city: MONDRAGON contact info Titolo: Dr. Nome: Chris Cognome: Merveille Email: send email Telefono: +34 943712400 Fax: +34943 796 944	ES (MONDRAGON)	participant	0.00
5	INTERUNIVERSITAIR MICRO-ELECTRONICACENTRUM IMEC VZW  Organization address address: KAPELDREEF 75 city: LEUVEN contact info Titolo: Mrs. Nome: Christine Cognome: Van Houtven Email: send email Telefono: +32 92643446	BE (LEUVEN)	participant	0.00
6	KUNGLIGA TEKNISKA HOEGSKOLAN  Organization address address: BRINELLVAGEN 8 city: STOCKHOLM contact info Titolo: Mrs. Nome: Marianne Cognome: Fridborn Email: send email Telefono: +46 85537 8447	SE (STOCKHOLM)	participant	0.00
7	LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN E.V.  Organization address address: Albert Einstein strasse 9 city: JENA contact info Titolo: Ms. Nome: Gabriele Cognome: Hamm Email: send email Telefono: +49 3641206327 Fax: +49 3641 206399	DE (JENA)	participant	0.00
8	MICROFLUIDIC CHIPSHOP GMBH  Organization address address: STOCKHOLMER STRASSE 20 city: JENA contact info Titolo: Dr. Nome: Claudia Cognome: Gärtner Email: send email Telefono: +49 3641 347050 Fax: +49 3641 3470590	DE (JENA)	participant	0.00
9	STOCKHOLMS LAENS LANDSTING  Organization address address: Hantverkargatan 45 city: STOCKHOLM contact info Nome: Erica Cognome: Oeqvist Email: send email Telefono: 46858586863	SE (STOCKHOLM)	participant	0.00
10	STOCKHOLMS UNIVERSITET  Organization address address: Universitetsvaegen 10 city: STOCKHOLM contact info Titolo: Ms. Nome: Ann Cognome: Nielsen Email: send email Telefono: 468162594	SE (STOCKHOLM)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

Through further development, integration and validation of micro-nano-bio and biophotonics systems from previous projects CanDo will develop an instrument that will permit the identification and concentration determination of rare cells in peripheral blood for two key societal challenges, early and low cost anti-cancer drug efficacy determination and cancer diagnosis/monitoring.A cellular link between the primary malignant tumor and the peripheral metastases, responsible for 90% of cancer-related deaths, has been established in the form of circulating tumor cells (CTCs) in peripheral blood. Furthermore the relatively short survival time of CTCs in peripheral blood means that their detection is indicative of tumor progression thereby providing in addition to a prognostic value an evaluation of therapeutic efficacy and early recognition of tumor progression in theranostics. In cancer patients however blood concentrations are very low (=1 CTC/1E9 cells) and current detection strategies are too insensitive, limiting use to prognosis of only those with advanced metastatic cancer. Similarly problems occur in therapeutics with anti-cancer drug development leading to lengthy and costly trials often preventing access to market. There is therefore a clear need for a novel analytical platform capable of highly reproducible and reliable identification of CTC concentrations of interest in an easily accessible format.With all relevant industrial stakeholders and users onboard CanDo is uniquely capable of delivering such a platform. Its novel cell separation/SERS analysis technologies plus nucleic acid based molecular characterization will provide an accurate CTC count with high throughput and high yield meeting both key societal challenges. Being beyond the state of art it will lead to substantial share gains not just in the high end markets of drug discovery and cancer diagnostics but due to modular technologies in others e.g. transport, security and safety and environment.